SPRY Stock Forecast: ARS Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for ARS Pharmaceuticals, Inc. is $17. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 13 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores ARS Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (44): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (10): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SPRY stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SPRY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | Cantor Fitzgerald | Maintains | Overweight | $30 → $20 |
| 6 Nov 2026 | Raymond James | Downgrade | Outperform | $28 → $17 |
| 13 Aug 2026 | Leerink Partners | Maintains | Outperform | $24 → $18 |
| 25 June 2026 | Leerink Partners | Maintains | Outperform | $25 → $24 |
| 28 May 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 4 Sept 2025 | Roth Capital | Initiates | Buy | — |
| 7 Mar 2025 | Scotiabank | Initiates | Sector Outperform | — |
| 14 Jan 2025 | Raymond James | Maintains | Strong Buy | — |
| 13 Jan 2025 | Leerink Partners | Maintains | Outperform | — |
| 8 Oct 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Sept 2024 | Leerink Partners | Maintains | Outperform | — |
| 16 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Aug 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 13 Aug 2024 | Raymond James | Upgrade | Strong Buy | — |
| 25 July 2024 | Raymond James | Initiates | Outperform | — |
| 11 Mar 2024 | Wedbush | Reiterates | Outperform | — |
| 5 Mar 2024 | Leerink Partners | Upgrade | Outperform | — |
| 13 Nov 2023 | Wedbush | Maintains | Outperform | — |
| 21 Sept 2023 | Wedbush | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SPRY.
This page is one stock. Monday covers all of them.
SPRY appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SPRY vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, ARS Pharmaceuticals, Inc. returned −56.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SPRY analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 2.4×
- Price / book
- 23.4×
- EV / EBITDA
- —
Cheaper than 43% of US stocks
Cheaper than 3% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 61.8%
- Operating margin
- —
- Net margin
- —
Higher than 75% of US stocks
- Return on equity
- −294.6%
- Return on assets
- −39.5%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ARS Pharmaceuticals, Inc. has a market value of $297.6M and an enterprise value of $356.2M.
Revenue in the twelve months to 30 June 2026: $116.9M. The latest quarter grew 114.2% year on year.
Net income over the same four quarters: −$215.4M, a −184.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$196.6M.
ARS Pharmaceuticals, Inc. employs 203 people — $576K of revenue per employee.
Data provided by Twelve Data
SPRY and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SPRY’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own ARS Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SPRY
What is the SPRY stock price forecast for 2026-2027?
The median 12-month analyst price target for ARS Pharmaceuticals, Inc. is $17, with estimates ranging from $14 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SPRY stock a buy right now?
Of the 4 analysts covering ARS Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ARS Pharmaceuticals, Inc. 13 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SPRY?
As at 21 Nov 2026, ARS Pharmaceuticals, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (44 of 100).
Will SPRY stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $17, and Ticker Nerd's factor model ranks ARS Pharmaceuticals, Inc. 13 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SPRY stock forecast for 2030?
No analyst covering ARS Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $20 over the next 12 months.
How has SPRY stock performed over the past year?
ARS Pharmaceuticals, Inc. returned -56.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ARS Pharmaceuticals, Inc. do?
Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention.
About ARS Pharmaceuticals, Inc.
Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention. Notable for its emphasis on creating user-friendly delivery mechanisms, Ars Pharmaceuticals tailors its offerings to both patients and healthcare professionals seeking reliable and effective emergency treatments. By addressing critical needs within the healthcare industry, Ars Pharmaceuticals plays a significant role in expanding options in allergy treatment and management. Its contributions to the medical field underscore its ongoing commitment to transforming therapeutic landscapes and meeting pressing health challenges.
CEO Mr. Donn Casale · 203 employees · United States · https://ars-pharma.com